title: Bortezomib-based antibody-mediated rejection therapy and simultaneous conversion to belatacept.
authors: 1 Work created as Transplant Pharmacy Fellow, Department of Surgery, Division of Transplantation, University of Cincinnati Academic Health Center, Cincinnati, OH 2 Transplant Clinical Research, University of Cincinnati Medical Center, Cincinnati, OH 3 Transplant Clinical Pharmacy, The Christ Hospital, Cincinnati, OH 4 Director of Kidney Transplantation, The Christ Hospital, Kidney and Hypertension Center, Cincinnati, OH 5 Director Division of Transplantation Department of Surgery, University of Cincinnati Medical Center, Cincinnati, OH.
authors: Jill C
authors: JC
authors: Krisl
authors: Rita R
authors: RR
authors: Alloway
authors: Adele Rike
authors: AR
authors: Shields
authors: Michael A
authors: MA
authors: Cardi
authors: E Steve
authors: ES
authors: Woodle
mesh_terms: D000069594:Abatacept; D000328:Adult; D001379:Azathioprine / Q000009:adverse effects; D001706:Biopsy; D001897:Boronic Acids / Q000008:administration & dosage*; D000069286:Bortezomib; D065095:Calcineurin Inhibitors; D016572:Cyclosporine / Q000009:adverse effects; D005922:Glomerulonephritis, IGA / Q000628:therapy; D006084:Graft Rejection / Q000517:prevention & control*; D006801:Humans; D018796:Immunoconjugates / Q000008:administration & dosage*; D007165:Immunosuppression Therapy / Q000379:methods; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D007674:Kidney Diseases / Q000175:diagnosis; D007676:Kidney Failure, Chronic / Q000628:therapy; D016030:Kidney Transplantation / Q000379:methods*; D008297:Male; D011241:Prednisone / Q000009:adverse effects; D011719:Pyrazines / Q000008:administration & dosage*; D016896:Treatment Outcome
chemical_list: D001897:Boronic Acids; D065095:Calcineurin Inhibitors; D018796:Immunoconjugates; D007166:Immunosuppressive Agents; D011719:Pyrazines; D000069286:Bortezomib; D000069594:Abatacept; D016572:Cyclosporine; D001379:Azathioprine; D011241:Prednisone